Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Hepatitis C.

Costa1, Schiff

  • 1Division of Hepatology, Center for Liver Diseases, University of Miami School of Medicine, 1500 NW 12th Ave., Suite 1101, Miami, FL 33136-1038, USA.

Current Treatment Options in Gastroenterology
|November 30, 2000
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Tuberculosis notifications among children and young adolescents, 2008-2019 compared to 2020-2023, Brazil.

Bulletin of the World Health Organization·2026
Same author

On the Changes Which Take Place in the Lungs after Division of the Pneumogastric Nerves.

Medical examiner (Philadelphia, Pa.)·2023
Same author

Single Brain Metastasis.

Current treatment options in neurology·2000
Same author

Hepatitis B Vaccination of Health Care Workers is Not Yet a Reality.

The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases·2000
Same author

Comparative Study of the Efficacy and Tolerability of Secnidazole Suspension (single dose) and Tinidazole Suspension (two days dosage) in the Treatment of Amebiasis in Children.

The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases·2000
Same author

Photoreduction and evolution of mercury from seawater

The Science of the total environment·2000
Same journal

Esophageal Disorders in the Older Adult.

Current treatment options in gastroenterology·2025
Same journal

Endobariatrics: a Still Underutilized Weight Loss Tool.

Current treatment options in gastroenterology·2023
Same journal

Management of Post Ablative Barrett's Esophagus: a Review of Current Practices and Look at Emerging Technologies.

Current treatment options in gastroenterology·2023
Same journal

Inflammatory Bowel Disease Therapy and Venous Thromboembolism.

Current treatment options in gastroenterology·2023
Same journal

Ileal Pouch-Anal Anastomosis in the Older Adult: a Review of Postoperative Outcomes and Pouchitis Treatment.

Current treatment options in gastroenterology·2023
Same journal

Celiac Disease in the Elderly.

Current treatment options in gastroenterology·2023
See all related articles

Hepatitis C virus (HCV) treatment with interferon and ribavirin aims for viral clearance and halting liver disease progression. Sustained virological response (SVR) signifies long-term remission and improved liver histology.

Area of Science:

  • Hepatology
  • Virology
  • Pharmacology

Background:

  • Chronic hepatitis C is a primary cause of end-stage liver disease and liver transplantation in the US.
  • Hepatitis C virus (HCV) infection poses risks for cirrhosis and hepatocellular carcinoma, necessitating treatment.
  • Current standard therapy involves interferon and ribavirin to achieve viral clearance and prevent liver damage.

Purpose of the Study:

  • To outline the treatment goals for hepatitis C virus (HCV) infection.
  • To define key response metrics: end of treatment response (ETR) and sustained virological response (SVR).
  • To identify predictors of treatment success and discuss associated risks.

Main Methods:

  • Combination therapy using recombinant alpha interferon and ribavirin.

Related Experiment Videos

  • Monitoring for biochemical and virological remission (ETR).
  • Assessing long-term outcomes, including histological improvement, 6 months post-treatment (SVR).

    • Main Results:

    • SVR is associated with significant and persistent histological improvement in patients.
    • HCV genotype, viral load, fibrosis stage, gender, and age predict treatment response.
    • Combination therapy can cause side effects including mood changes, fatigue, and blood count abnormalities.

    Conclusions:

    • Achieving SVR is the ultimate goal of HCV therapy, leading to improved liver health.
    • Treatment efficacy is influenced by patient-specific factors and viral characteristics.
    • Careful monitoring for side effects and adherence to safety precautions, such as contraception due to ribavirin's teratogenicity, are crucial.